Vitrakvi (larotrectinib)

New case report – successful limb salvage of a child with infantile fibrosarcoma using Larotrectinib @drshubhamsahni @samdoc_mamc https://t.co/g0f4GGrWFh (@ecancer)

Fantastic learning programme from @DrEzraCohen ! Updates on #NTRK fusions in #thyroidcancer with a focus on: ✅Treatments such as #entrectinib and #larotrectinib ✅ Histopathology ✅Efficacy and safety of treatment Watch and download the slides here👇 https://t.co/KEY6lBsvUT (@PresOnc_Connect)

#ASCO23 | Hall A | Sunday 8am CT Long-term Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer Jessica Lin, MD (@JessicaJLinMD) ➡️ https://t.co/I4j2RKV3WG @ASCO #MGCCatASCO23 (@MGHCancerCenter)

🎙️ In this JCO PO Conversations podcast episode, host @thenasheffect speaks with @alexdrilon about his JCO PO article "Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers" 🎧 Take a listen ➡️ https://t.co/JEuabTW4St (@JCOPO_ASCO)

Dr. @RobertoFerrara_ at #RomeLung23 discusses #NTRK as a viable target in NSCLC with two approved drugs: larotrectinib and entrectinib. Still unraveling primary and acquired resistance but newer agents like repotrectinib showing promise. (@StephenVLiu)

@DavidHongMD discusses updated findings from an analysis of 3 trials which ultimately led to the approval of #larotrectinib for patients with solid tumors who harbor an #NTRK fusion. #lcsm | @MDAndersonNews https://t.co/k1oP43s5t8 (@TargetedOnc)

I think it is unlikely that there were any secretory TNBC cases in the Mammaprint training data. The NTRK angle is interesting. You need a trial of adjuvant larotrectinib for breast like the ADAURA trial for EGFR mutant resected lung ca. (@UnfrznCavemanMD)

Report of a case of #NTRK fusion squamous NSCLC with primary resistance to larotrectinib in #JTOCRR. Analysis suggest a subclonal NTRK+ population with another NTRK-negative population. Interesting, but also troubling. @JTOonline @MaryBoulanger4 @IbiayiMD https://t.co/uAClJDpT0X (@StephenVLiu)

Larotrectinib available in ⁦@ASCO⁩ #TAPUR for NTRK amplified advanced solid tumors. https://t.co/PIcc7Sqlra (@rschilsky)

Se refiere a Larotrectinib y Entrectinib, 2 fármacos muy activos en tumores con fusiones de NTRK. Y tiene razón: “Nos están denegando posibilidades de vida”, la queja de pacientes con sarcoma por un nuevo fármaco. ⁦@asargasarcoma⁩ ⁦@sanidadgob⁩ https://t.co/jFslumSAwU (@OncoLucus)

New learning programme from @DrEzraCohen ! Updates on #NTRK fusions in #thyroidcancer with a focus on: 1.Treatments such as #entrectinib and #larotrectinib 2. Histopathology 3. Efficacy and safety of treatment Watch and download the slides here👇 https://t.co/phO74f4VJ5 (@ntrkconnectinfo)

@alexdrilon discussed NTRK fusions in solid tumors, collective findings of studies assessing #larotrectinib for the treatment of these fusions, and how to conduct genomic testing to identify patients who might benefit from TRK inhibitor therapy. #lcsm https://t.co/YngHUi76Io (@TargetedOnc)

Check out new programme from @DrEzraCohen on #NTRK fusions in thyroid cancer, with emphasis on using #nextgenerationsequencing to screen for NTRK Click the link for data on targeted therapies like entrectinib & larotrectinib 👇 https://t.co/8it3wIO5kV (@ntrkconnectinfo)

#NSCLC shows promising intracranial response to the #NTRK inhibitor #larotrectinib. Assessing intracranial response to therapy is challenging. Our goal is improve the management of patients with CNS leptomeningeal #metastasis (LM) with #CNSide. #brainmet (@MikeDuganMD)

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC [Aug 7, 2022] @DavidHongMD @OncLive https://t.co/XZLII46pMk #NTRK #PrecisionMedicine #lcsm HT @VivekSubbiah (@mtmdphd)

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC [Aug 7, 2022] @DavidHongMD @OncLive https://t.co/XZLII45RWM #NTRK #PrecisionMedicine #lcsm HT @VivekSubbiah (@mtmdphd)

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC [August 7, 2022] @DavidHongMD @OncLive https://t.co/XZLII45RWM #NTRK #PrecisionMedicine #lcsm HT @VivekSubbiah (@mtmdphd)

Dr. Hong on the Significance of Larotrectinib in NTRK-Positive NSCLC https://t.co/Ql8Ub8HX2k via @onclive (@VivekSubbiah)

🤔What if the tumor is #MSI-High & has a #TRK-FUSION🛻 🧬❓ 🆕Published today🗞👇🏾 #ColorectalCancer❌response to #Immunotherapy (Pembro & IPI➕NIVO) ➡️brisk & CURATIVE response to NTRK⛔️Larotrectinib. #ctDNA #CRCSM #PrecisionMedicine @OncoAlert Link: https://t.co/wr6wyAFa0K (@pashtoonkasi)

#ASCO22, thanks @alexdrilon for the great presentation on updated efficacy and safety results with #larotrectinib in #TRK+ fusion lung cancer. Thanks all speakers in #NSCLC: Testing is the key to find these lung patients who can benefit from efficient treatment. #NTRK #MedEd (@ntrkconnectinfo)

#ASCO22 Closes with a comment on reimbursement for entrectinib or larotrectinib in #NTRK NSCLC and says it is "crazy" to not reimburse based on efficacy and that waiting for a randomized trial in this rare subtype is inappropriate. #LCSM (@StephenVLiu)

#ASCO22 Last abstract in this section is #9024 from Dr. @alexdrilon highlighting update on larotrectinib in #NTRK NSCLC: RR 83%, mPFS and mOS not reached. Fairly comparable to entrectinib data. Unique toxicities with NTRK inhibition important to remember. (@StephenVLiu)

Excelente poster discussion en otros targets en NSCLC. Actualización de eficacia entrectinib B-FAST cohorte ROS1+ (ORR 81.5%, <mPFS y mOS por criterio selección ctDNA+ > tumor burden). Actualización Larotrectinib NTRK+ (ORR 83%,mOS 40.7m). #ASCO2022 @BenjaminBesseMD (@aaoncoclinica)

#ASCO22 Closes with a comment on reimbursement for entrectinib or larotrectinib in #NTRK NSCLC and says it is "crazy" to not reimburse based on efficacy and that waiting for a randomized trial in this rare subtype is inappropriate. #LCSM (@StephenVLiu)

#ASCO22 Last abstract in this section is #9024 from Dr. @alexdrilon highlighting update on larotrectinib in #NTRK NSCLC: RR 83%, mPFS 14.6m, mOS 40.7m. Fairly comparable to entrectinib data. Unique toxicities with NTRK inhibition important to remember. (@StephenVLiu)

Interesting case of #NTRK infantile sarcoma @JCOPO_ASCO. Transient responses to larotrectinib and selitrectinib with acquired NTRK resistance mutations noted after each TKI. Durable response to selitrectinib plus MEK inhibitor trametinib. https://t.co/lzRU4mopCk (@StephenVLiu)

Encouraging data for #NTRK inhibition in NSCLC presented by Dr. @alexdrilon at #RomeLung22. Both entrectinib and larotrectinib have shown efficacy and manageable toxicity, enough to warrant 1L use. Next gen inhibitors to target resistance include repotrectinib and selitrectinib. (@StephenVLiu)

12-month child with unresectable leg #infantile #fibrosarcoma with ETV6- NTRK3 fusion, post 2 mths of #larotrectinib, #Partial Response @NTRKers @ntrkconnectinfo @RashiKapoor17 @DrManasKalra1 @VivekSubbiah #precision #oncology #sarcoma #limb #salvage (@samdoc_mamc)

Here our E-learning about the importance of identifying #NTRK fusions in patients with #sarcoma and #lungcancer to benefit from targeted #TRK therapy: Entrectinib, larotrectinib and more... #MedEd 👇 https://t.co/jcbUX9X9U2 Thanks: @RobinL_Jones, @ChristianRolfo & Erin Rudzinski (@ntrkconnectinfo)

Patients with advanced lung cancers whose tumors harbor NTRK gene fusions experienced durable responses, survival benefit, and a favorable safety profile with larotrectinib treatment. @alexdrilon #lcsm https://t.co/wQ7MyTq3Dz (@TargetedOnc)

@alexdrilon & co published the #larotrectinib data in #NTRK positive #lungcancer Interestingly we released a podcast with @ChristianRolfo & @catemarchio discussing screening for #NTRK fusions and treatment for #lcsm tumours. Check out the podcast here: https://t.co/wEf9eJVx3T (@ntrkconnectinfo)

Dr. @karenkellymd reviews #NTRK in NSCLC at #TTLC22. Two approved and highly active agents available (entrectinib, larotrectinib) with novel agents designed to overcome (and maybe prevent) resistance. (@StephenVLiu)

The first publication of larotrectinib in NTRK fusion+ lung cancers alone is out. Beyond the initial systemic & intracranial response gains, the ~35 month median PFS and the ~41 month median OS impress. Wonderful news for patients, advocates, and providers across the world. (@alexdrilon)

50 year old male Non Smoker Metastatic Ca Lung. Adenocarcinom having NTRK fusion positive. Do we have any provision of getting Larotrectinib on compassionate basis.@sujithonco @aparna96 @batraatulmd @StephenVLiu @rakesh_boya @Priya1111 @Prasshmehta (@drrifu)

Larotrectinib in NTRK Fusion+ NSCLC: - 20 nsclc pts from 3 early ph trials - ORR 73% (1 CR, 10 PRs) - mDOR 33.9mo; PFS 35.4mo; mOS 40.7mo NTRK may be a needle in a haystack, but if u find it- it’s a golden needle 🙏🏼 ⁦@OncoAlert⁩ #LCSM https://t.co/MJejUFt9f6 (@DrJNaidoo)

Update on larotrectinib in #NTRK+ NSCLC @JCOPO_ASCO. In 20pts with NSCLC and a TRK fusion treated with larotrectinib, RR 73%, mDOR 34m, mPFS 35m, mOS 41m, mTTR 1.8m. Worth making sure NTRK fusions are included in your biomarker panel for NSCLC! #LCSM https://t.co/9BID2sOTwe (@StephenVLiu)

#CTOS2021: @KummarShivaani et al present an updated efficacy & safety data of #larotrectinib in 33 #NTRK positive #sarcoma patients Data cut-off: 20Jul20 --> ORR= 65% --> 24m PFS rate= 55% Ccl: Durable and robust responses! Treatment is efficacious: need to find those patients! (@ntrkconnectinfo)

4/4 💥Now 👉Patient-driven discovery + post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive #lungcancer 🧬🎯💥 Larotrectinib+ Selpercatinib in NTRK + RET fusion 🫁 @Annals_Oncology https://t.co/vITKsvBjw7 (@VivekSubbiah)

In #ColorectalCancer 2️⃣ scenarios #TumorBoardTuesday that these fusions are enriched in: 1️⃣ #NTRK in MSI⬆️ 2️⃣ Acquired fusions post EGFR⛔️ in RAS/RAF-wildtype 🔁 testing or #ctDNA🩸🧬 can be of value. Here’s my NTRK-#CRCSM still NED 2 years post-IO progression👇🏾➡️larotrectinib. https://t.co/zcjvp7gV2x (@pashtoonkasi)

Larotrectinib in a Patient With Advanced NTRK translocated Pleomorphic #Liposarcoma of the Uterus ⁦@gtinocomd⁩ https://t.co/5z5bFzLdpF (@JTrentMDPhD)

Larotrectinib shows promise in NTRK-positive primary CNS tumors. @AshleySumrallMD of @LevineCancer discusses early data that raises hope for several types of difficult-to-treat brain tumors. https://t.co/4P0MeAwQbh #BTSM #ASCODailyNews (@ASCO)

Larotrectinib has proved to be highly active in patients with thyroid cancer with NTRK gene fusions, exhibiting rapid and durable disease control. @DrMCabanillas @MDAndersonNews https://t.co/liI4UDGAPJ (@OncLive)